(17 days)
Not Found
No
The summary describes a quantitative immunoassay and associated instruments for measuring IgE levels. There is no mention of AI or ML in the intended use, device description, or performance studies. The instruments are described as processing assay steps and calculating results automatically, which is standard automation and not indicative of AI/ML.
No
This device is an in vitro diagnostic assay used for measuring IgE levels to aid in the diagnosis of allergic disorders, not for therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that ImmunoCAP Specific IgE and ImmunoCAP Total IgE are "intended for in vitro diagnostic use."
No
The device description explicitly mentions reagents, carriers, solutions, and instruments (Phadia 100, 1000, 2500, 5000) which are hardware components used in the assay process. The software is associated with these instruments, not a standalone software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use / Indications for Use: Both ImmunoCAP Specific IgE and ImmunoCAP Total IgE are explicitly stated as "in vitro quantitative assay" and "in vitro test system" respectively. They are intended for "in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders".
- Device Description: The description details reagents and instruments used to perform the assay on human serum or plasma samples, which are biological specimens.
- Intended User / Care Setting: The intended user is "clinical laboratories," which is a typical setting for IVD testing.
The information provided clearly indicates that this device is designed to be used outside of the body to examine specimens from the human body for diagnostic purposes, which is the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum or plasma (EDTA or Na-Heparin). ImmunoCAP Specific IgE is to be used with instruments Phadia 100, Phadia 1000, Phadia 2500 and Phadia 5000. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories.
ImmunoCAP Total IgE is an in vitro test system for the quantitative measurement of circulating total IgE in human serum and plasma. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories. ImmunoCAP Total IgE is to be used with the instruments Phadia 100, Phadia 1000, Phadia 2500 or Phadia 5000.
Product codes (comma separated list FDA assigned to the subject device)
DHB, DGC
Device Description
ImmunoCAP Specific IgE and ImmunoCAP Total IgE are in vitro diagnostic assays.
Assay reagents: The general ImmunoCAP reagents include ImmunoCAP Specific or Total IgE Conjugate, ImmunoCAP Specific or Total IgE Curve Control, ImmunoCAP Specific or Total IgE Calibrators, Specific or Total IgE anti-IgE, Allergen ImmunoCAP carriers (only for determination of Specific IgE), Development solution, Stop Solution and Washing Solution. The method specific reagents consist of individual purified allergen (native or recombinant), covalently coupled to a support in a plastic housing (only for determination of Specific IgE).
Instrument System: Phadia 100, Phadia 250, Phadia 2500 and Phadia 5000 instruments with associated software process all steps of the assay and calculate results automatically after the assay is completed.
ImmunoCAP Specific IgE, Test Principle: The allergen of interest, covalently coupled to ImmunoCAP, reacts with the specific IgE in the patient sample. After washing away non-specific IgE, enzyme labeled antibodies against IgE are added to form a complex. After incubation, unbound enzyme-anti-IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The higher the response value, the more specific IgE is present in the specimen. To evaluate the test results, the responses for the patient samples are transformed to concentrations with the use of a calibration curve.
ImmunoCAP Total IgE, Test Principle: Anti-IgE covalently coupled to ImmunoCAP, reacts with the total IgE in the patient sample. After washing, enzyme labeled antibodies against IgE are added to form a complex. Following incubation, unbound enzyme-anti IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The higher the response value, the more IgE is present in the sample. To evaluate the test results, the responses for the patient samples are transformed to concentrations with the use of a calibration curve.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratories
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The New Device, IgE calibrators traceable to 30 WHO IRR was compared with the Predicate Device, IgE calibrators traceable to 2nd WHO IRR, in two separate studies:
- Concentration determination of two stock solutions used for production of ImmunoCAP Specific IgE Calibrators
- Evaluation of clinical negative and positive patient samples in ImmunoCAP Specific IgE
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5510 Immunoglobulins A, G, M, D, and E immunological test system.
(a)
Identification. An immunoglobulins A, G, M, D, and E immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the immunoglobulins A, G, M, D, an E (serum antibodies) in serum. Measurement of these immunoglobulins aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, overlapping each other. The profiles are simple and abstract, and they are arranged in a way that suggests unity and collaboration.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 28, 2016
PHADIA AB MARTIN MANN REGULATORY AFFAIRS MANAGER 4169 COMMERCIAL AVENUE PORTAGE, MI 49002
Re: K161889
Trade/Device Name: ImmunoCAP Specific IgE Assay and ImmunoCAP Total IgE Assay Regulation Number: 21 CFR 866.5750 Regulation Name: Radioallergosorbent (RAST) immunological test system Regulatory Class: Class II Product Code DHB, DGC Dated: July 8, 2016 Received: July 11, 2016
Dear Mr. Mann:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809]); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements
1
as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Kelly Oliner -S
For.
Leonthena Carrington, MS, MBA, MT(ASCP) Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name ImmunoCAP Specific IgE
Indications for Use (Describe)
ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum or plasma (EDTA or Na-Heparin). ImmunoCAP Specific IgE is to be used with instruments Phadia 100, Phadia 1000, Phadia 2500 and Phadia 5000. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | |
|---|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Indications for Use
510(k) Number (if known)
Device Name ImmunoCAP Total IgE
Indications for Use (Describe)
ImmunoCAP Total IgE is an in vitro test system for the quantitative measurement of circulating total IgE in human serum and plasma. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories. ImmunoCAP Total IgE is to be used with the instruments Phadia 100, Phadia 1000, Phadia 2500 or Phadia 5000.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/0 description: The image shows the logo for Thermo Fisher Scientific. The words "Thermo Fisher" are in red, and the word "SCIENTIFIC" is in gray. The logo is simple and modern.
Special 510(k) Submission, Reference Material Change for ImmunoCAP Total IgE and ImmunoCAP Specific IgE Assays A.7 510k Summary
510(k) Summary
This summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR Part 807.92.
Premarket Notification 510(k) No:
| Date of Summary Preparation: | July 7, 2016 |
|---|---|
| Manufacturer: | Phadia AB |
| Rapsgatan 7P | |
| P.O. Box 6460 | |
| 751 37 Uppsala, Sweden | |
| US Distributor: | Phadia US Inc. |
| 4169 Commercial Avenue | |
| Portage, MI 49002 | |
| Company contact person: | Martin Mann |
| Regulatory Affairs Manager | |
| Phadia US Inc. | |
| 269-492-1957 | |
| martin.mann@thermofisher.com |
Device Name (1):
ImmunoCAP Specific IgE
Common Name:
Automated in vitro quantitative assay for the measurement of allergen specific IgE antibodies.
| Classification:
Product Code
Class
| CFR | DHB |
|---|---|
| II | |
| 866.5750 | |
| Substantial Equivalence to: | |
| ImmunoCAP Specific IgE | K051218 |
Indications For Use / Intended Use Statement
ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific lgE in human serum or plasma (EDTA or Na-Heparin). ImmunoCAP Specific IgE is to be used with instruments Phadia 100, Phadia 1000, Phadia 2500 and Phadia 5000. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories.
5
Image /page/5/Picture/0 description: The image shows the logo for Thermo Fisher Scientific. The words "Thermo Fisher" are in red, and the word "SCIENTIFIC" is in gray. The logo is simple and modern.
Special 510(k) Submission, Reference Material Change for ImmunoCAP Total IgE and ImmunoCAP Specific IgE Assays A.7 510k Summarv
Device Name (2): ImmunoCAP Total IgE
Common name:
Automated in vitro quantitative assay for the measurement of Total IgE
| Classification: | |
|---|---|
| Product code | DGC |
| Class | II |
| CFR | 866.5510 |
| Substantial Equivalence to: | K133404 |
| ImmunoCAP Total IgE |
Indications For Use / Intended Use Statement
ImmunoCAP Total IgE is an in vitro test system for the quantitative measurement of circulating total lgE in human serum and plasma. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories. ImmunoCAP Total IgE is to be used with the instruments Phadia 100, Phadia 250, Phadia 1000, Phadia 2500 or Phadia 5000.
Device Description
Assav reagents
The general ImmunoCAP reagents include ImmunoCAP Specific or Total IgE Conjugate, ImmunoCAP Specific or Total IgE Curve Control, ImmunoCAP Specific or Total IgE Calibrators, Specific or Total IgE anti-IgE, Allergen ImmunoCAP carriers (only for determination of Specific IgE), Development solution, Stop Solution and Washing Solution. The method specific reagents consist of individual purified allergen (native or recombinant), covalently coupled to a support in a plastic housing (only for determination of Specific IgE).
Instrument System
Phadia 100, Phadia 250, Phadia 2500 and Phadia 5000 instruments with associated software process all steps of the assay and calculate results automatically after the assay is completed.
ImmunoCAP Specific IgE, Test Principle
The allergen of interest, covalently coupled to ImmunoCAP, reacts with the specific IgE in the patient sample. After washing away non-specific IgE, enzyme labeled antibodies against IgE are added to form a complex. After incubation, unbound enzyme-anti-IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The higher the response value, the more specific IgE is present in the specimen. To evaluate the test results, the responses for the patient samples are transformed to concentrations with the use of a calibration curve.
lmmunoCAP Total IgE, Test Principle
Anti-IgE covalently coupled to ImmunoCAP, reacts with the total IgE in the patient sample. After washing, enzyme labeled antibodies against IgE are added to form a complex. Following
6
Image /page/6/Picture/0 description: The image contains the logo for Thermo Fisher Scientific. The words "Thermo Fisher" are in red, and the word "SCIENTIFIC" is in gray below it. The logo is simple and modern.
Special 510(k) Submission, Reference Material Change for ImmunoCAP Total IgE and ImmunoCAP Specific IgE Assays A.7 510k Summarv
incubation, unbound enzyme-anti IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The higher the response value, the more IgE is present in the sample. To evaluate the test results, the responses for the patient samples are transformed to concentrations with the use of a calibration curve.
Description of change
Introduction of a new Reference Material for standardization of ImmunoCAP Specific and Total IgE assays, the 3th WHO International Standard (300 WHO IRR) for serum IgE (11/234). No change of Intended Use/Indications for Use or fundamental scientific technology of the assay system has been made. No change of specifications or manufacturing methods for any assay reagents has been made.
Directions for Use for ImmunoCAP Specific and ImmunoCAP Total IgE will be updated to reflect the change. The update will be phased in over time. During a transition period Phadia intends to supply an intermediate version of labelling containing traceability information to either the old and new reference material.
Performance characteristics
The New Device, IgE calibrators traceable to 30 WHO IRR was compared with the Predicate Device, IgE calibrators traceable to 2nd WHO IRR, in two separate studies:
- Concentration determination of two stock solutions used for production of ImmunoCAP ● Specific IgE Calibrators
- . Evaluation of clinical negative and positive patient samples in ImmunoCAP Specific IgE
Conclusion
The safety and effectiveness of the cleared ImmunoCAP Specific and Total IgE systems, intended for the determination of specific and total IgE antibodies, have been established in previous 510(k) submissions. The Reference Material change does not affect the Intended Use or the Indications for Use statements, the fundamental scientific technology, specifications or manufacturing methods of the assays. The verification studies performed demonstrate that the updated ImmunoCAP Specific and Total IgE assays are substantially equivalent to the currently cleared products.